Updated:
Developed with DRL, it reduces oxygen-dependence in patients
Share Article
AAA
Defence Minister Rajnath Singh hands over the first batch of 2-DG anti Covid drug to the Union Health Minister Harsh Vardhan, in New Delhi on May 17, 2021. Photo: Twitter/@rajnathsingh
Developed with DRL, it reduces oxygen-dependence in patients
The first batch of the adjunct COVID therapy drug, 2-deoxy-D-glucose (2-DG) developed by the Defence Research and Development Organisation (DRDO) along with Dr Reddy’s Laboratories (DRL), Hyderabad was on Monday released for emergency use. Defence Minister Rajnath Singh formally handed over the drug to Health Minister Dr Harsh Vardhan.
“One box each of the sachets of the drug were handed over to Dr. Randeep Guleria, Director All India Institute of Medical Sciences (AIIMS) and Lt. Gen. Sunil Kant of Armed Forces Medical Services (AFMS). More will be handed over to different hospitals across the country for emergency use,” a Defence M
›Delhi govt has written to Dr Reddy s for 67 lakh doses of Sputnik V vaccine: Arvind Kejriwal
Delhi govt has written to Dr Reddy s for 67 lakh doses of Sputnik V vaccine: Arvind Kejriwal
SECTIONS
Delhi govt has written to Dr Reddy s for 67 lakh doses of Sputnik V vaccine: Arvind KejriwalPTI
Last Updated: May 15, 2021, 09:58 PM IST
Share
Synopsis
Kejriwal s announcement came after Deputy Chief Minister Manish Sisodia earlier this week claimed that Covaxin manufacturer Bharat Biotech has refused to provide additional doses to the national capital.
Agencies
Kejriwal said experience of many countries shows that coronavirus infection can be reduced through mass vaccination.
On a consolidated basis, Dr Reddy s Laboratories net profit dropped 28% to Rs 553.50 crore on 7% increase in revenues to Rs 4,728.40 crore in Q4 March 2021 over Q4 March 2020.
Profit before tax jumped 13% to Rs 807.10 crore in Q4 FY21 as against Rs 714.20 crore in Q4 FY20. EBITDA rose 13.15% to Rs 1,133 crore in Q4 FY21 over Q4 FY20. EBITDA margin stood 24% in Q4 FY21 higher than 22.6% in Q4 FY20.
Revenue in the Global Generics (CG) segment rose 6% to 3873.70 crore in Q4 FY21 over Q4 FY20. The YoY growth was driven by branded markets (India and emerging markets), while Europe was partly offset by decline in North America Generics (NAG).
First doses of Sputnik V administered in India. Deepak Sapra, Global Head of Custom Pharma Services at Dr Reddy s Laboratories receives the first jab of the vaccine in Hyderabad. (ANI)
HYDERABAD: With the Sputnik V Covid-19 vaccine receiving clearance in India, Deepak Sapra, Global Head of Custom Pharma Services at Dr Reddy s Laboratories received the first jab of the vaccine in Hyderabad.
The first consignment of imported doses of Sputnik V vaccine landed in India on May 1 received regulatory clearance from the Central Drugs Laboratory at Kasauli in Himachal Pradesh on May 13.
As per a statement, imported doses of the Sputnik V Covid-19 vaccine are presently priced at Rs 948 (+5 per cent GST) per dose, with the possibility of a lower price point when local supply begins.
Dr. Reddy s Laboratories (DRL) along with its subsidiaries announced the launch of Ertapenem for Injection, a therapeutic equivalent generic version of INVANZ.
INVANZ is a trademark of Merck and Co., Inc. The INVANZ brand and generic market had U.S. sales of approximately $205 million MAT for the most recent twelve months ending in March 2021 according to IQVIA Health.
Dr. Reddy s Ertapenem for Injection, 1 g/vial, is available in packs of 10 vials per carton.
Dr. Reddy s Laboratories along with its subsidiaries announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).